Satellos Bioscience Inc.
🇨🇦XTSE.MSCLCanadaHealthcare
PriceCA$12.50+0.16 (+1.3%)
Latest anomalies
Neutral 0 detected in the last 120 days
- High: 0
- Medium: 0
- Low: 0
No anomaly detected for this instrument.
Free with a Finzer account.
Profile
- Healthcare
- Biotechnology
- Canada
Identity
- Exchange
- Toronto Stock Exchange . XTSE
- Type
- Stock
- ISIN
- CA80401L3083
- CUSIP
- Not reported
Company
- Employees
- 14
- Headquarters
- Toronto, Canada
- Website
- https://satellos.com
Market
- Shares outstanding
- 176.3M
- Market cap
- CA$2.2B
Highlights
- Market cap
- CA$2.18B
- EPS LTM
- -CA$0.13calculatedCalculated by Finzer, not reported by the data provider.
- P/E LTM
- -95.00calculatedCalculated by Finzer, not reported by the data provider.
- Div yield
- Not reported
Fundamentals (LTM)
- Revenue
- CA$0
- Net income
- -CA$23.2M-9.78%down year on year
- Gross margin
- Not reported
- Free cash flow
- -CA$5.66M+72.32%up year on year
Latest news
News is not sourced for this exchange.
Business summary
Satellos Bioscience Inc. is a company in the healthcare sector, listed on Toronto Stock Exchange (Canada) under the ticker MSCL. Its market capitalisation is CA$2.2B, from 176.3M shares outstanding, as of . Across the 250 trading sessions to the shares traded between CA$7.56 and CA$18.98, and the last close of CA$12.50 sits 43% of the way up that range. The company is headquartered in Toronto, Canada, and employs about 14 people.
Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247 an oral, small-molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research Institute (OHRI); and an option agreement with the University of British Columbia. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.